Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

NCCN Guidelines (R) Insights Myeloproliferative Neoplasms, Version 2.2018 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Mesa, R. A., Jamieson, C., Bhatia, R., Deininger, M. W., Fletcher, C. D., Gerds, A. T., Gojo, I., Gotlib, J., Gundabolu, K., Hobbs, G., McMahon, B., Mohan, S. R., Oh, S., Padron, E., Papadantonakis, N., Pancari, P., Podoltsev, N., Rampal, R., Ranheim, E., Reddy, V., Rein, L. M., Scott, B., Snyder, D. S., Stein, B. L., Talpaz, M., Verstovsek, S., Wadleigh, M., Wang, E. S., Bergman, M., Gregory, K. M., Sundar, H. 2017; 15 (10): 1193–1207

Abstract

Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.

View details for DOI 10.6004/jnccn.2017.0157

View details for Web of Science ID 000412320900005

View details for PubMedID 28982745